Biopharmaceutical Royalties

SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...

VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...

NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...